29 completed, 10 recruiting, 9 not yet recruiting, 9 terminated. 28 Phase 3, 17 Phase 2, 10 Phase 1, 7 Not applicable, 7 Phase 4.
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO) Atorvastatin - Graves Disease, Graves Disease (Basedow's Disease) | Phase 2 | Not yet recruiting | Region Skane | 554 | 2026-11-01 | 2026-10-20 |
| Transconjunctival Versus Transcutaneous Betamethasone for Upper Eyelid Retraction in TED Betamethasone - Thyroid Eye Disease | Not applicable | Not yet recruiting | Assiut University | 54 | 2026-10-10 | 2026-10-08 |
| An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab veligrotrug (LUMVOA™) - Thyroid Eye Disease | Phase 4 | Not yet recruiting | Viridian Therapeutics, Inc. | 30 | 2026-09-01 | 2026-09-21 |
| Study of Atorvastatin and Its Effects in Clinical and Radiological Aspects in Patients With Moderate-to-Severe Thyroid Eye Disease Atorvastatin, methylprednisolone (IVMP) - Thyroid Eye Disease, Graves Ophthalmopathy | Phase 1 | Not yet recruiting | Banu Aji Dibyasakti | 64 | 2026-08-30 | 2026-08-13 |
| A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Active Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease | Phase 3 | Not yet recruiting | Beijing Kanghong Biological Medicine Co., Ltd. | 60 | 2026-08-01 | 2026-07-23 |
| A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease KHN939, Placebo - Thyroid Eye Disease | Phase 3 | Not yet recruiting | Beijing Kanghong Biological Medicine Co., Ltd. | 117 | 2026-08-01 | 2026-07-23 |
| A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease Teprotumumab N01, Methylprednisolone - Thyroid Eye Disease | Phase 4 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 92 | 2026-07-30 | 2026-08-13 |
| Clinical Validation of AI-Based Quantitative Eye Movement Analysis From Smartphone 9-Gaze Videos (Glandy EOM) Glandy EOM (AI-based quantitative eye movement analysis software) - Ocular Motility Disorders, Strabismus | Not yet recruiting | THYROSCOPE INC. | 1000 | 2026-07-01 | 2026-06-03 | |
| A Study of IBI3031 in Participants With Thyroid Eye Disease IBI3031, placebo - Thyroid Eye Disease | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 66 | 2026-06-30 | 2026-07-14 |
| An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease AMG 732 - Thyroid Eye Disease | Phase 2 | Recruiting | Amgen | 30 | 2026-05-07 | 2026-07-23 |
| An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) NTB003, NTB003 and Placebo - Thyroid Eye Disease | Phase 1 / Phase 2 | Not yet recruiting | Nanjing Chia-tai Tianqing Pharmaceutical | 74 | 2026-03-01 | 2026-03-10 |
| Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease Teprotumumab Injection [Tepezza] - Thyroid Eye Disease, Thyroid Eye Disease, TED | Phase 4 | Not yet recruiting | Sheba Medical Center | 40 | 2026-01-01 | 2025-12-30 |
| Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye Disease 68Ga-FAPI PET/CT and PET/MR Imaging, 68Ga-DOTATATE PET/CT and PET/MR Imaging - Thyroid Eye Disease | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 50 | 2025-11-14 | 2026-09-23 | |
| Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. [18F]AlF-NOTA-FAPI-04PET/CT, 5.0-T high-resolution MRI - Thyroid Eye Disease | Not applicable | Recruiting | Peking University Third Hospital | 50 | 2025-11-11 | 2026-02-20 |
| A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease IBI311, Placebo - Thyroid Eye Disease | Phase 3 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 111 | 2025-09-10 | 2025-11-17 |
| Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients Teprotumumab - Thyroid Eye Disease | Completed | Amgen | 5 | 2025-07-02 | 2025-09-08 | |
| A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) VRDN-003, Autoinjector - Thyroid Eye Disease | Phase 3 | Completed | Viridian Therapeutics, Inc. | 87 | 2025-07-01 | 2026-06-25 |
| Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) Kamuvudine-9 - Thyroid Eye Disease | Phase 1 | Terminated | Peter Timoney | 4 | 2024-11-06 | 2026-04-01 |
| A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease Lu AG22515 - Thyroid Eye Disease | Phase 1 | Active not recruiting | H. Lundbeck A/S | 20 | 2024-09-19 | 2026-09-09 |
| A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease IBI311 (20 mg), IBI311 (3-20 mg), IBI311 (10 mg) - Thyroid Eye Disease | Phase 2 | Completed | Innovent Biologics (Suzhou) Co. Ltd. | 38 | 2024-09-04 | 2025-10-03 |
Showing 20 of 73. Sign in to see all of them.
Graves Ophthalmopathy (73) · Graves Disease (10) · Exophthalmos (8) · Eye Diseases (5) · Thyroid Diseases (4) · Autoimmune Diseases (3) · Endocrine System Diseases (3) · Hyperthyroidism (3) · Orbital Diseases (3) · Hashimoto Disease (2) · Asthma (1) · Bronchiolitis Obliterans Syndrome (1) · Diplopia (1) · Eyelid Diseases (1) · Glaucoma (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (73) · Eye Diseases, Hereditary (73) · Genetic Diseases, Inborn (73) · Goiter (73) · Immune System Diseases (73) · Autoimmune Diseases (70) · Endocrine System Diseases (70) · Hyperthyroidism (70) · Orbital Diseases (70) · Thyroid Diseases (69) · Eye Diseases (68) · Exophthalmos (65) · Graves Disease (63) · Lung Diseases (3) · Respiratory Tract Diseases (3)
teprotumumab (10) · Methylprednisolone (3) · Saline Solution (3) · Sodium Chloride (3) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (2) · Atorvastatin (2) · Selenium (2) · satralizumab (2) · tocilizumab (2) · Betamethasone (1) · Bimatoprost (1) · Celecoxib (1) · Injections (1) · Latanoprost (1) · Lubricant Eye Drops (1)
Amgen (10) · Viridian Therapeutics, Inc. (8) · Innovent Biologics (Suzhou) Co. Ltd. (5) · Assiut University (3) · Immunovant Sciences GmbH (3) · Beijing Kanghong Biological Medicine Co., Ltd. (2) · Hoffmann-La Roche (2) · Iran University of Medical Sciences (2) · Peking University Third Hospital (2) · Sheba Medical Center (2) · Sling Therapeutics, Inc. (2) · argenx (2) · ACELYRIN Inc. (1) · All India Institute of Medical Sciences, Bhubaneswar (1) · Ameera Gamal Abdelhameed (1)
United States (38) · Spain (19) · China (17) · Germany (17) · United Kingdom (14) · Poland (13) · Italy (12) · Australia (11) · France (10) · Hungary (7) · Canada (5) · Japan (5) · Israel (4) · Latvia (4) · Turkey (Türkiye) (4)
Mohsen B Kashkouli, MD (2) · Ahmed Abdelal, MD (1) · Ahmed Abdelnasser, Lecturer (1) · Andrea L. Kossler, M.D. (1) · Dalia Mohammed, Professor (1) · Daniel Rootman (1) · Donald O Kikkawa, MD (1) · Hui Li, Dr. (1) · Karim Meeran, MBBS BSc MD (1) · Khaled Abdelazim, Assistant professor (1)
PMID 41066062, PMID 12608932, PMID 12848966, PMID 14398978, PMID 17057811, PMID 18299459, PMID 20181974, PMID 21215658, PMID 21730841, PMID 21852080, PMID 22124787, PMID 22443978, PMID 22752189, PMID 23253433, PMID 23874630, PMID 24145858, PMID 27797318, PMID 31971679, PMID 33172865, PMID 33574798, PMID 33768488, PMID 35604323, PMID 36479875, PMID 38613579, PMID 41066129, PMID 42117357, PMID 42448986, PMID 42837042
2023 (6), 2017 (2), UL1TR000005 (1)